INT879

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1978
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 16
Total Number 18
Disease Relevance 1.11
Pain Relevance 12.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Fdft1) endoplasmic reticulum (Fdft1) transferase activity, transferring alkyl or aryl (other than methyl) groups (Fdft1)
Anatomy Link Frequency
brain 3
hypothalamus 2
AVPv 1
cerebral cortex 1
duodenum 1
Fdft1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 178 100.00 Very High Very High Very High
substance P 73 100.00 Very High Very High Very High
Calcitonin gene-related peptide 65 100.00 Very High Very High Very High
Neuropeptide 29 100.00 Very High Very High Very High
Serotonin 12 100.00 Very High Very High Very High
Enkephalin 8 100.00 Very High Very High Very High
Dopamine 5 100.00 Very High Very High Very High
Cholecystokinin 4 100.00 Very High Very High Very High
nociceptor 8 99.90 Very High Very High Very High
unmyelinated 2 99.66 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nociception 50 93.92 High High
Hyperplasia 3 91.68 High High
Immunization 2 91.36 High High
Pain 46 76.24 Quite High
Polycystic Ovary Syndrome 14 60.64 Quite High
INFLAMMATION 1 60.24 Quite High
Stress 24 54.96 Quite High
Hyperalgesia 2 45.20 Quite Low
Urological Neuroanatomy 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immunocytochemical localization of substance P (SP), neurotensin (NT), met-enkephalin (m-ENK), somatostatin (SS) and vasoactive intestinal polypeptide (VIP) revealed all of these peptides within discrete regions of the Ce.
Localization (localization) of SS associated with somatostatin, enkephalin, amygdala and substance p
1) Confidence 0.59 Published 1983 Journal Peptides Section Abstract Doc Link 6196761 Disease Relevance 0 Pain Relevance 0.55
Both morphine (10 microM) and dopamine (50 microM) significantly inhibited the potassium-evoked release of SS from the cerebral cortex, without affecting its basal release.
Localization (release) of SS in cerebral cortex associated with dopamine, somatostatin, cerebral cortex and morphine
2) Confidence 0.59 Published 1981 Journal Brain Res. Section Abstract Doc Link 6114785 Disease Relevance 0 Pain Relevance 0.81
The release of [3H]NA from cortical slices differed from that of somatostatin (SS) in its K+-dependency, with the release of SS having a higher threshold.
Localization (release) of SS associated with somatostatin
3) Confidence 0.59 Published 1981 Journal Brain Res. Section Abstract Doc Link 6114785 Disease Relevance 0 Pain Relevance 0.79
Regulation of somatostatin (SS) secretion was studied in an in vitro system using collagenase-dispersed cells from fetal rat hypothalamus maintained in long term monolayer culture.
Localization (secretion) of SS in hypothalamus associated with somatostatin
4) Confidence 0.25 Published 1983 Journal Endocrinology Section Abstract Doc Link 6129132 Disease Relevance 0 Pain Relevance 0.43
GABAergic, cholinergic, and serotoninergic systems may thus interact at the level of the hypothalamus to modulate SS secretion in vivo and thereby influence anterior pituitary release of GH and TSH.
Localization (secretion) of SS in hypothalamus associated with gabaergic and somatostatin
5) Confidence 0.21 Published 1983 Journal Endocrinology Section Abstract Doc Link 6129132 Disease Relevance 0 Pain Relevance 0.67
Cultured cells exhibit a measurable basal secretion of immunoactive SS (SSLI) which can be augmented by carbachol, acetylcholine, or oxotremorine.
Localization (secretion) of SS associated with somatostatin
6) Confidence 0.19 Published 1983 Journal Endocrinology Section Abstract Doc Link 6129132 Disease Relevance 0 Pain Relevance 0.55
Cysteamine, which has been reported to deplete SS content and to increase SS release in brain, augmented the basal and evoked release of ACh from hippocampal slices, without affecting SS-like content and release.
Localization (release) of SS in brain associated with somatostatin
7) Confidence 0.17 Published 1990 Journal J. Neurochem. Section Abstract Doc Link 1976754 Disease Relevance 0 Pain Relevance 1.34
Cysteamine, which has been reported to deplete SS content and to increase SS release in brain, augmented the basal and evoked release of ACh from hippocampal slices, without affecting SS-like content and release.
Localization (release) of SS in brain associated with somatostatin
8) Confidence 0.17 Published 1990 Journal J. Neurochem. Section Abstract Doc Link 1976754 Disease Relevance 0 Pain Relevance 1.32
The brain tissue was then reacted immunocytochemically to localize neurotensin (NT), substance P (SP), methionine enkephalin (ENK), vasoactive intestinal polypeptide (VIP), somatostatin (SS), and cholecystokinin octapeptide (CCK).
Localization (localize) of SS in brain associated with somatostatin, enkephalin, cholecystokinin and substance p
9) Confidence 0.13 Published 1989 Journal Peptides Section Abstract Doc Link 2474157 Disease Relevance 0 Pain Relevance 0.97
In the present study we evaluated the distribution of biochemically specific cells and fibers within the AVPv and adjacent regions by using an indirect immunohistochemical method with antisera to serotonin (5-HT), dopamine beta-hydroxylase (DBH), tyrosine hydroxylase (TH), neuropeptide Y (NPY), cholecystokinin-8 (CCK), vasoactive intestinal polypeptide (VIP), substance P (SP), neurotensin (NT), corticotropin-releasing factor (CRF), luteotropin-releasing hormone (LRH), somatostatin (SS), thyrotropin-releasing hormone (TRH), oxytocin (OXY), vasopressin (VAS), adrenocorticotropic hormone (ACTH1-24), alpha-melanocyte-stimulating hormone (alpha-MSH), leucine-enkephalin (L-ENK), and calcitonin gene-related peptide (CGRP).
Localization (using) of SS in AVPv associated with dopamine, somatostatin, enkephalin, calcitonin gene-related peptide, neuropeptide, serotonin, cholecystokinin and substance p
10) Confidence 0.10 Published 1987 Journal Brain Res. Section Abstract Doc Link 2880634 Disease Relevance 0 Pain Relevance 0.72
The present investigation examined the distributions of immunoreactive neurotensin (NT), cholecystokinin octapeptide (CCK), substance P (SP), methionine enkephalin (ENK), vasoactive intestinal polypeptide (VIP), somatostatin (SS), rat neurophysin II (RNP II), vasopressin (VP), oxytocin (OXY), tyrosine hydroxylase (TH), and serotonin in the parabrachial nuclear complex (PB) of the rat.
Spec (examined) Localization (distributions) of SS associated with somatostatin, enkephalin, serotonin, cholecystokinin, parabrachial and substance p
11) Confidence 0.10 Published 1987 Journal Peptides Section Abstract Doc Link 2884646 Disease Relevance 0 Pain Relevance 0.64
In particular, activation of alpha 2-adrenoceptors stimulates GH secretion via endogenous GHRH release, although a mechanism operating to inhibit hypothalamic SS release cannot be excluded; stimulation of alpha 1-adrenoceptors is inhibitory to GH secretion exclusively via an increased release of hypothalamic SS.
Localization (release) of SS associated with somatostatin
12) Confidence 0.07 Published 1987 Journal Endocrinology Section Abstract Doc Link 2881775 Disease Relevance 0 Pain Relevance 0.38
In particular, activation of alpha 2-adrenoceptors stimulates GH secretion via endogenous GHRH release, although a mechanism operating to inhibit hypothalamic SS release cannot be excluded; stimulation of alpha 1-adrenoceptors is inhibitory to GH secretion exclusively via an increased release of hypothalamic SS.
Localization (release) of SS associated with somatostatin
13) Confidence 0.07 Published 1987 Journal Endocrinology Section Abstract Doc Link 2881775 Disease Relevance 0 Pain Relevance 0.31
Fresh frozen tissue sections from the duodenum were processed in an attempt to demonstrate the presence of SS receptors in mast cells using immunofluorescence and Fluo-peptide labeling techniques.
Localization (presence) of SS in duodenum associated with somatostatin
14) Confidence 0.06 Published 2003 Journal Regul. Pept. Section Abstract Doc Link 12609751 Disease Relevance 0.23 Pain Relevance 0.50
Intraileal (SS-IL) infusion of SS at 48 micrograms/kg-1h-1 did not inhibit stimulated pancreatic secretion but was rather stimulatory possibly through the inhibition of putative ileal inhibitors.
Localization (secretion) of SS-IL associated with somatostatin
15) Confidence 0.05 Published 1989 Journal Endocrinology Section Abstract Doc Link 2565219 Disease Relevance 0.15 Pain Relevance 0.88
Density levels and distribution of CGRP-, SP-, SS- and GABAB2-IR were quantified and, for all sections, background density measurements were subtracted to these values.


Localization (distribution) of SS associated with somatostatin, substance p and calcitonin gene-related peptide
16) Confidence 0.04 Published 2009 Journal Mol Pain Section Body Doc Link PMC2727498 Disease Relevance 0.06 Pain Relevance 0.45
After peripheral noxious stimulation of unmyelinated nociceptors the release of calcitonin gene-related peptide (CGRP) [7], substance P (SP) [8] and somatostatin (SS) [4,9] is increased although it remains largely unchanged after innocuous stimulation or stimulation of large myelinated fibres [8,9].
Localization (release) of SS in nociceptors associated with nociceptor, somatostatin, unmyelinated, substance p and calcitonin gene-related peptide
17) Confidence 0.04 Published 2009 Journal Mol Pain Section Body Doc Link PMC2727498 Disease Relevance 0.67 Pain Relevance 1.21
On the other hand, pretreatment with anti-TRH did not affect the basal serum GH levels nor the anti-SS-induced GH release.
Localization (release) of anti-SS
18) Confidence 0.03 Published 1978 Journal Endocrinology Section Abstract Doc Link 107024 Disease Relevance 0 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox